Antimetastatic drugs in prostate cancer

Clinical Prostate Cancer

Volumn 1, Issue 1, 2002, Pages 14-19

  Chay, Christopher H ^b   Cooper, Carlton C ^b   Hellerstedt, Beth A ^b   Pienta, Kenneth J ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b 7303 CCGC 0946 ^*

Author keywords

Angiogenesis inhibitors; Bisphosphonates; Metalloproteinase inhibitors; Metastasis; Prostate cancer

Indexed keywords

ALENDRONIC ACID; ANGIOGENESIS INHIBITOR; BATIMASTAT; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; ETIDRONIC ACID; IBANDRONIC ACID; IMATINIB; MARIMASTAT; METALLOPROTEINASE INHIBITOR; MITOXANTRONE; OLPADRONIC ACID; PAMIDRONIC ACID; PECTIN; PLACEBO; PREDNISONE; PRINOMASTAT; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; SEMAXANIB; THALIDOMIDE; TRASTUZUMAB; ZOLEDRONIC ACID;

BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL INTERACTION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FATIGUE; HUMAN; HYPERGLYCEMIA; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; METASTASIS; MUSCULOSKELETAL DISEASE; NEPHROTOXICITY; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOSIS;

EID: 0042383370     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2002.n.002     Document Type: Review

References (52)

1. Miyake H, Hara I, Kamidono S, et al. Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting anti-apoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity. Int J Urol 2001; 8:337-349.
2. Ko YJ, Small EJ, Kabbinavar F, et al. A multi-institutional phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res 2001; 7:800-805.
3. Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6:4885-4892.
4. George DJ, Dionne CA, Jani J, et al. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res 1999; 59:2395-2401.
5. Gong MC, Chang SS, Watt F, et al. Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy. Mol Urol 2000; 4:217-222.
6. Olson KA, Byers HR, Key ME, et al. Prevention of human prostate tumor metastasis in athymic mice by antisense targeting of human angiogenin. Clin Cancer Res 2001; 7: 3598-3605.
7. Figg WD, Dahut W, Duray P, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001; 7:1888-1893.
8. Figg WD, Arlen P, Gulley J, et al. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol 2001; 28:62-66.
9. Rosen L, Kabbinavar F, Rosen P, et al. Phase I trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies. Proc Am Soc Clin Oncol 1998; 17:218a (Abstract #843).
10. Nemunaitis J, Poole C, Primrose J, et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 1998; 4:1101-1109.
11. Boasberg P, Harbaugh, Eisenberger M, et al. Marimastat in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 1997; 16:316a (Abstract #1126).
12. Ahmann F, Saad F, Mercier R, et al. Interim results of a phase III study of the matrix metalloprotease inhibitor prinomastat in patients having metastatic, hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 2001; 20:174a (Abstract #692).
13. Pienta KJ, Naik H, Akhtar A, et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst 1995; 87:348-353.
14. Saad F, Murray R, Venner P, et al. Zoledronic acid is effective in the treatment of bone metastases from prostate cancer: results of a large phase III, double-blind, randomized trial, American Association of Cancer Research Special Conference New Discoveries in Prostate Cancer Biology and Treatment, Naples, FL, December 5-9, 2001.
15. Pegram MD, Konecny G, Slamon DJ. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of Herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res 2000; 103:57-75.
16. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-242.
17. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031-1037.
18. Gopalkrishnan RV, Kang DC, Fisher PB. Molecular markers and determinants of prostate cancer metastasis. J Cell Physiol 2001; 189:245-256.
19. Ellis LM, Fidler IJ. Angiogenesis and metastasis. Eur J Cancer 1996; 32A:2451-2460.
20. Cooper CR, Pienta KJ. Cell adhesion and chemotaxis in prostate cancer metastasis to bone: a minireview. Prostate Cancer and Prostatic Disease 2000; 3:6-12.
21. Lehr JE, Pienta KJ. Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst 1998; 90:118-123.
22. Stein CA. Mechanisms of action of taxanes in prostate cancer. Semin Oncol 1999; 26:3-7.
23. Fett JW, Strydom DJ, Lobb RR, et al. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry 1985; 24:5480-5486.
24. Olson KA, French TC, Vallee BL, et al. A monoclonal antibody to human angiogenin suppresses tumor growth in athymic mice. Cancer Res 1994; 54:4576-4579.
25. Pienta KJ. Preclinical mechanisms of action of decetaxel and docetaxel combinations in prostate cancer. Semin Oncol 2001; 28:3-7.
26. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. Pathol 1999; 189:300-308.
27. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000; 10:415-433.
28. Hoekstra R, Eskens FA, Verweij J. Matrix metalloproteinase inhibitors: current developments and future perspectives. Oncologist 2001; 6:415-427.
29. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93:178-193.
30. Gohji K, Fujimoto N, Hara I, et al. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer 1998; 79:96-101.
31. Knox JD, Bretton L, Lynch T, et al. Synthetic matrix metalloproteinase inhibitor, BB-94, inhibits the invasion of neoplastic human prostate cells in a mouse model. Prostate 1998; 35:248-254.
32. Nemeth JA, Yousif R, Herzog M, et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2002; 94:17-25.
33. Drummond AH, Beckett P, Brown PD, et al. Preclinical and clinical studies of MMP inhibitors in cancer. Ann N Y Acad Sci 1999; 878:228-235.
34. O'Leary J, Young D, Shalinsky D, et al. Identification of membrane type-matrix metalloproteinase-1 (MT-MMP-1) in human prostate cancer and in vivo inhibition of PC3 cell invasion and angiogenesis by AG3340. Proc Am Soc Clin Oncol 1999; 18:312a (Abstract #1198).
35. Honn KV, Tang DG. Adhesion molecules and tumor cell interaction with endothelium and subendothelial matrix. Cancer Metastasis Rev 1992; 11:353-375.
36. Chay CH, Pienta KJ. Evidence for lectin signaling to the nuclear matrix: cellular interpretation of the glycocode. J Cell Biochem 2000; 35 (suppl):123-129.
37. Berruti A, Dogliotti L, Tucci M, et al. Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. J Urol 2001; 166:2023-2031.
38. Charhon SA, Chapuy MC, Delvin EE, et al. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer 1983; 51:918-924.
39. Ikeda I, Miura T, Kondo I. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. Br J Urol 1996; 77: 102-106.
40. Boissier S, Magnetto S, Frappart L, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997; 57:3890-3894.
41. Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000; 60:2949-2954.
42. Adami S, Salvagno G, Guarrera G, et al. Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol 1985; 134:1152-1154.
43. Smith JA, Jr. Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J Urol 1989; 141:85-87.
44. Clarke NW, McClure J, George NJ. Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer. Br J Urol 1992; 69:64-70.
45. Kylmala T, Tammela T, Risteli L, et al. Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer 1993; 29A:821-825.
46. Lipton A, Glover D, Harvey H, et al. Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast of prostate cancer. Ann Oncol 1994; 5 (suppl 7):S31-35.
47. Vinholes JJ, Purohit OP, Abbey ME, et al. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 1997; 8:1243-1250.
48. Adami S. Bisphosphonates in prostate carcinoma. Cancer 1997; 80: 1674-1679.
49. Pelger RC, Hamdy NA, Zwinderman AH, et al. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone 1998; 22:403-408.
50. Coleman RE, Purohit OP, Black C, et al. Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. Ann Oncol 1999; 10: 311-316.
51. Fielding J, Scholefield J, Stuart R, et al. A randomized double-blind placebo-controlled study of marimastat in patients with inoperable gastric adenocarcinoma. Proc Am Soc Clin Oncol 2000; 19:240a (Abstract #929).
52. Rosemurgy A, Buckels J, Charnley R, et al. A randomized study comparing marimaastat to gemcitabine as first line therapy in patients with non-resectable pancreatic cancer. Proc Am Soc Clin Oncol 1999; 18:261a (Abstract #1005).